Novo Nordisk to launch cheaper version of long-acting insulin in US

A new unbranded version of Tresiba means the Danish drugmaker now offers branded and unbranded versions of both rapid- and long-acting insulins in the hope that all US patients can afford the essential drug.

Photo: Hannah Beier/Reuters/Ritzau Scanpix

Less advantaged US patients will gain access to a more affordable medicine to treat and control diabetes, announces Novo Nordisk’s subsidiary in the US.

In fall of this year, patients holding prescriptions for Tresiba (insulin degludec), a long-acting basal insulin injection, will have the option to pick up an unbranded, cheaper, version at pharmacies. The unbranded biologic was approved by the US Food and Drug Administration (FDA) in June, and will launch at 65% of the cost of its branded counterpart.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs